Interventions for idiopathic steroid-resistant nephrotic syndrome in children

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 11, 2019, Pages

  Liu, Isaac D ^a   Willis, Narelle S ^b,c   Craig, Jonathan C ^c,d   Hodson, Elisabeth M ^b,c  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DEXAMETHASONE; ENALAPRIL; FISH OIL; FOSINOPRIL; GALACTOSE; INDOMETACIN; IRBESARTAN; LEFLUNOMIDE; LIVER ENZYME; MYCOPHENOLATE MOFETIL; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; ROSIGLITAZONE; SPARSENTAN; TACROLIMUS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; ALOPECIA; BACTERIAL INFECTION; BRAIN DISEASE; BRONCHOSPASM; CATARACT; CLINICAL PRACTICE; CONGENITAL NEPHROTIC SYNDROME; COUGHING; CUSHINGOID SYNDROME; CYSTITIS; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG FATALITY; DRUG MEGADOSE; DYSPNEA; GLAUCOMA; HAIR LOSS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; INJECTION SITE REACTION; KIDNEY FAILURE; LACK OF DRUG EFFECT; LEUKOPENIA; LOW DRUG DOSE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PEDIATRICS; PENILE SWELLING; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RECURRENCE RISK; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; URTICARIA; ADOLESCENT; CHILD; DRUG RESISTANCE; INFANT; META ANALYSIS; NEPHROTIC SYNDROME; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DRUG RESISTANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; NEPHROTIC SYNDROME; PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 85075448430     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003594.pub6     Document Type: Review

References (155)

1. Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W, et al. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft fur Padiatrische Nephrologie. Pediatric Nephrology 2008;23(9):1483-93. [MEDLINE: 18481113]x-wiley/crsRef/3333532
2. Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatric Nephrology 2004;19(1):45-50. [MEDLINE: 14648339]x-wiley/crsRef/3333534
3. Bagga A, Mudigoudar BD, Vasudev V, Hari P. Low (LD) versus high dose (HD) enalapril therapy in steroid resistant nephrotic syndrome (SRNS) [abstract]. 7th Asian Congress of Pediatric Nephrology; 2000 Nov 4-6; Singapore. 2000. [CENTRAL: CN-00583291]x-wiley/crsRef/3333535
4. Bhaumik SK, Majumdar A, Barman SC. Comparison of pulse methyl prednisolone vs cyclosporin based therapy in steroid resistant focal segmental glomerulosclerosis [abstract]. Indian Journal of Nephrology 2002;12(4):190. [CENTRAL: CN-00460392]x-wiley/crsRef/3333594
5. Chongviriyaphan N, Tapaneya-Olarn C, Suthutvoravut U, Karnchanachumpol S, Chantraruksa V. Effects of tuna fish oil on hyperlipidemia and proteinuria in childhood nephrotic syndrome. Journal of the Medical Association of Thailand 1999;82 Suppl 1:S122-8. [MEDLINE: 10730531]x-wiley/crsRef/3333537
6. Choudhry A, Bagga A, Menon S, Hari P. Randomized controlled trial (RCT) on efficacy and safety of cyclosporin (CyA) vs tacrolimus (Tac) in steroid resistant nephrotic syndrome (SRNS) [CRG030600042] [abstract no: 182 (OP)]. Pediatric Nephrology 2007;22(9):1480. [CENTRAL: CN-00653722]x-wiley/crsRef/3333539
7. Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. American Journal of Kidney Diseases 2009;53(5):760-9. [MEDLINE: 19268410]x-wiley/crsRef/3333540
8. Gesualdo L, Lieberman K, Tesar V, Srivastava T, Komers R. Antiproteinuric effect of sparsentan, a dual angiotensin II and endothelin type A receptor antagonist, in patients with primary focal segmental glomerulosclerosis (FSGS): a subgroup analysis of the DUET trial [abstract no: TO042]. Nephrology Dialysis Transplantation 2017;32(Suppl 3):iii97. [EMBASE: 617290819]x-wiley/crsRef/12315173
9. Hogan JJ, Derebail VK, Murphy E, Raguram PC, Pergola PE, Sanghani NS, et al. Long-term effects of sparsentan, a dual angiotensin and endothelin receptor antagonist in primary focal segmental glomerulosclerosis (FSGS): interim 84-week analysis of the DUET trial [abstract no: FR-OR087]. Journal of the American Society of Nephrology 2018;29(Abstracts Suppl):61. x-wiley/crsRef/12315174
10. Karol M, Pan-Zhou XR, Tuller SE, Komers R. Sparsentan pharmacokinetics and pharmacodynamics as the basis of dose selection for primary focal segmental glomerular sclerosis (FSGS) [abstract no: SA-PO635]. Journal of the American Society of Nephrology 2017;28(Abstract Suppl):843. x-wiley/crsRef/12315175
11. Komers R, Gipson DS, Nelson P, Adler S, Srivastava T, Derebail VK, et al. Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET). Kidney International Reports 2017;2(4):654-64. [MEDLINE: 29142983]x-wiley/crsRef/12315176
12. Tesar V, Trachtman H, Murphy E, Ferguson B, Komers R. No impact of newly initiated immunosuppressive therapy observed on long-term antiproteinuric effect of sparsentan in focal segmental glomerulosclerosis: interim 84-week analysis of the DUET trial [abstract no: SUN-037]. Kidney International Reports 2019;4(7 Suppl):S168-9. [EMBASE: 2002180135]x-wiley/crsRef/12315177
13. Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, et al. DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. Journal of the American Society of Nephrology 2018;29(11):2745-54. [MEDLINE: 30361325]x-wiley/crsRef/12315178
14. Trachtman H, Nelson PJ, Komers R. Efficacy and safety of sparsentan, a dual angiotensin II (Ang II) and endothelin (ET) type A receptor antagonist in patients with focal segmental glomerulosclerosis (FSGS): a phase 2 trial (DUET) [abstract no: HI-OR06]. Journal of the American Society of Nephrology 2016;27(Abstract Suppl):2B. x-wiley/crsRef/12315179
15. Trachtman H, Rychlik I, Haws R, Nester C, Fornoni A, Komers R. Newly administered immunosuppressive therapy (IST) has no impact on long-term antiproteinuric effect of sparsentan (SPAR), a dual angiotensin and endothelin receptor antagonist, in patients with primary focal segmental glomerulosclerosis (FSGS): interim analysis of the DUET trial [abstract no: FP129]. Nephrology Dialysis Transplantation 2018;33(Suppl 1):i20. [EMBASE: 622606410]x-wiley/crsRef/12315180
16. Trachtman H, Rychlik I, Haws RM, Nester CM, Fornoni A, Komers R. Long-term effect of sparsentan (SPAR), a dual angiotensin and endothelin receptor antagonist, on proteinuria in patients with primary FSGS: interim analysis of the DUET trial [abstract no: FR-OR026]. Journal of the American Society of Nephrology 2017;28(Abstract Suppl):44. x-wiley/crsRef/12315181
17. Elhence R, Gulati S, Kher V, Gupta A, Sharma RK. Intravenous pulse cyclophosphamide - a new regime for steroid-resistant minimal change nephrotic syndrome. Pediatric Nephrology 1994;8(1):1-3. [MEDLINE: 8142205]x-wiley/crsRef/3333542
18. Gupta A, Elhence R, Kher V, Gulati S, Sharma RK. IV cyclophosphamide - a new regimen for steroid nonresponsive minimal change disease [abstract]. 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:84. x-wiley/crsRef/3333543
19. Gassman JJ, Trachtman H, Gipson D, Friedman A, Greene T, Vento S, et al. Implementing a second randomized trial enrolling mid-study treatment failures from the Focal Segmental Glomerular Sclerosis (FSGS) clinical trial [abstract no: 33]. Clinical Trials (London, England) 2007;4(4):382. [CENTRAL: CN-00794067]x-wiley/crsRef/12315183
20. Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, et al. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clinical Journal of the American Society of Nephrology: CJASN 2009;4(1):39-47. [MEDLINE: 19073787]x-wiley/crsRef/12315184
21. Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. American Journal of Kidney Diseases 2010;55(1):50-60. [MEDLINE: 19932542]x-wiley/crsRef/12315185
22. Ternant D, Paintaud G, Trachtman H, Gipson DS, Joy MS. A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). European Journal of Clinical Pharmacology 2016;72(2):253-5. [MEDLINE: 26521258]x-wiley/crsRef/12315186
23. Trachtman H, Gipson D, Vento S, Thompson A, Dike M. Novel therapies in resistant FSGS: preliminary results [abstract no: 879 (P)]. Pediatric Nephrology 2007;22(9):1629. [CENTRAL: CN-00794725]x-wiley/crsRef/12315187
24. Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, et al. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrology 2011;12:8. [MEDLINE: 21310077]x-wiley/crsRef/12315189
25. Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, et al. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the FONT clinical trial group. BMC Nephrology 2015;16:111. [MEDLINE: 26198842]x-wiley/crsRef/12315190
26. D'Agati VD, Alster JM, Jennette JC, Thomas DB, Pullman J, Savino DA, et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clinical Journal of the American Society of Nephrology: CJASN 2013;8(3):399-406. [MEDLINE: 23220425]x-wiley/crsRef/12315192
27. Ferris M, Norwood V, Radeva M, Gassman JJ, Al-Uzri A, Askenazi D, et al. Patient recruitment into a multicenter randomized clinical trial for kidney disease: report of the focal segmental glomerulosclerosis clinical trial (FSGS CT). Clinical & Translational Science 2013;6(1):13-20. [MEDLINE: 23399084]x-wiley/crsRef/12315193
28. Gassman J, Fine R, Gibson D, Greene T, Hogg R, Kaskel F, et al. A preliminary report of the focal segmental glomerulosclerosis clinical trial (FSGS-CT) [abstract no: F-PO1984]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):559A. [CENTRAL: CN-00790759]x-wiley/crsRef/12315194
29. Gassman JJ, Trachtman H, Gipson D, Friedman A, Greene T, Vento S, et al. Implementing a second randomized trial enrolling mid-study treatment failures from the Focal Segmental Glomerular Sclerosis (FSGS) Clinical Trial [abstract no: 33]. Clinical Trials 2007;4(4):382. [CENTRAL: CN-00767231]x-wiley/crsRef/12315195
30. Gipson D, Radeva M, Fine R, Friedman A, Gassman J, Greene T, et al. Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) study cohort [abstract no: TH-PO165]. Journal of the American Society of Nephrology 2009;20(Abstracts issue):147-8A. [CENTRAL: CN-00793840]x-wiley/crsRef/12315196
31. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney International 2011;80(8):868-78. [MEDLINE: 21734640]x-wiley/crsRef/12315197
32. Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, et al. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney International 2011;79(6):678-85. [MEDLINE: 21178977]x-wiley/crsRef/12315198
33. Greene T, Gassman J, Gipson D, Hogg R, Kaskel F, Moxey-Mims M, et al. Multicenter randomized clinical trial of FSGS in children and young adults [abstract no: F-PO1014]. Journal of the American Society of Nephrology 2005;16:558A. [CENTRAL: CN-00794633]x-wiley/crsRef/12315199
34. Hogg RJ, Friedman A, Greene T, Radeva M, Budisavljevic MN, Gassman J, et al. Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS. Clinical Journal of the American Society of Nephrology: CJASN 2013;8(2):211-8. [MEDLINE: 23143503]x-wiley/crsRef/12315200
35. Kopp JB, Winkler CA, Zhao X, Radeva MK, Gassman JJ, D'Agati VD, et al. Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS Clinical Trial. Journal of the American Journal of Nephrology 2015;26(6):1443-8. [MEDLINE: 25573908]x-wiley/crsRef/12315201
36. Kopp JB, Zhao X, Winkler CA, Woroniecki R, Radeva M, Gassman JJ, et al. APOL1 variant-associated FSGS is more aggressive but manifests similar response to cyclosporine and mycophenolate compared to others forms of primary FSGS [abstract no: FR-OR050]. Journal of the American Society of Nephrology 2012;23(Abstract Suppl):41A. x-wiley/crsRef/12315202
37. Middleton JP, Yorgin P, Gipson D, Radeva M, Fine R, Friedman A, et al. Prevalence of blood pressure (BP) control in the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) study cohort [abstract]. Journal of the American Society of Nephrology 2009;20(Abstracts issue):148A. [CENTRAL: CN-00795224]x-wiley/crsRef/12315203
38. Radeva M, McMahan J, Gassman J. Optimizing logistics under a three level administration system: coordination of the Focal Segmental Glomerular Sclerosis (FSGS) trial [abstract no: P63]. Clinical Trials (London, England) 2007;4(4):417-8. [CENTRAL: CN-00794883]x-wiley/crsRef/12315204
39. Radeva M, Trachtman H, Fine R, Friedman A, Gassman J, Gipson D, et al. Measuring quality of life (QOL) in children and young adults in the focal segmental glomerulosclerosis clinical trial (FSGS-CT) [abstract]. Clinical Trials 2010;7(4):471. [EMBASE: 70462847]x-wiley/crsRef/12315205
40. Sethna CB, Boone V, Kwok J, Jun D, Trachtman H. Adiponectin in children and young adults with focal segmental glomerulosclerosis. Pediatric Nephrology 2015;30(11):1977-85. [MEDLINE: 26115618]x-wiley/crsRef/12315206
41. Trachtman H, Fine R, Friedman A, Gassman J, Gipson D, Greene T, et al. Quality of life in children with focal segmental glomerulosclerosis (FSGS): baseline findings. Report of the FSGS-Clinical Trial (CT) [abstract no: TH-PO164]. Journal of the American Society of Nephrology 2009;20(Abstracts issue):147A. [CENTRAL: CN-00795355]x-wiley/crsRef/12315207
42. Woroniecki R, Du Z, Radeva M, Gassman JJ, Gipson DS, Trachtman H, et al. Osteopontin (OPN) and transforming growth factor beta 1 (TGFb1) in steroid resistant primary focal segmental glomerulosclerosis (FSGS), FSGS-clinical trial (FSGS-CT) experience [abstract no: SA-PO390]. Journal of the American Society of Nephrology 2012;23(Abstract Suppl):727A. x-wiley/crsRef/12315208
43. Garin EH, Orak JK, Hiott KL, Sutherland SE. Cyclosporine therapy for steroid-resistant nephrotic syndrome. A controlled study. American Journal of Diseases of Children 1988;142(9):985-8. [MEDLINE: 3046332]x-wiley/crsRef/3333559
44. Gulati A, Bagga A, Nephrotic Syndrome Study Group. Multicenter randomized controlled trial comparing efficacy of tacrolimus to intravenous cyclophosphamide in children with steroid resistant nephrotic syndrome [abstract no: LB-OR03]. Journal of the American Society of Nephrology 2011;22(Abstracts):1B. [CENTRAL: CN-01657678]x-wiley/crsRef/12315209
45. Gulati A, Hari P, Kanitkar M, Sharma J, Mantan M, Bagga A. Randomized, multicenter study on tacrolimus & alternate day (AD) prednisolone vs. intravenous (IV) cyclophosphamide & ad prednisolone for steroid resistant nephrotic syndrome (SRNS) [abstract no: 43]. Pediatric Nephrology 2010;25(9):1803. [EMBASE: 70438145]x-wiley/crsRef/12315210
46. Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney International 2012;82(10):1130-5. [MEDLINE: 22763815]x-wiley/crsRef/3333562
47. Abramowicz M, Barnett HL, Edelmann CM Jr, Greifer I, Kobayashi O, Arneil GC, et al. Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children. Lancet 1970;1(7654):959-61. [MEDLINE: 4191931]x-wiley/crsRef/3333564
48. Arneil GC. International trial of azathioprine in nephrotic syndrome in childhood [abstract]. Nephron 1971;8:95. [CENTRAL: CN-00602053]x-wiley/crsRef/3333565
49. Prospective, controlled trial of cyclophosphamide therapy in children with the nephrotic syndrome. Report of the International Study of Kidney Disease in Children. Lancet 1974;2(7878):423-7. [MEDLINE: 4137139]x-wiley/crsRef/3333567
50. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatric Nephrology 1996;10(5):590-3. [MEDLINE: 8897562]x-wiley/crsRef/3333569
51. Kleinknecht C, Broyer M, Gubler MC, Palcoux JB. Irreversible renal failure after indomethacin in steroid-resistant nephrosis. New England Journal of Medicine 1980;302(12):691. [MEDLINE: 6986554]x-wiley/crsRef/3333571
52. Kleinknecht C, Broyer M, Palcoux JB, Gubler MC. Irreversible renal failure (RF) after indomethacin in steroid resistant nephrosis (SRN) [abstract]. Kidney International 1979;16(1):96. [CENTRAL: CN-00446116]x-wiley/crsRef/3333572
53. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. Journal of the American Society of Nephrology 1996;7(1):56-63. [MEDLINE: 8808110]x-wiley/crsRef/3333574
54. Tejani A, Lieberman K. A randomized placebo (PL) controlled double blind trial of cyclosporine (CSA) in steroid resistant (SR) idiopathic focal segmental glomerulosclerosis (FSGS) in children. A report of the New York, New Jersey Pediatric Nephrology Collaborative Study Group [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):289. [CENTRAL: CN-00520391]x-wiley/crsRef/3333575
55. Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, et al. Rituximab in children with resistant idiopathic nephrotic syndrome. Journal of the American Society of Nephrology 2012;23(6):1117-24. [MEDLINE: 22581994]x-wiley/crsRef/3333577
56. Mantan M, Bagga A, Hari P. Efficacy of IV pulse cyclophosphamide (CP) vs IV steroids and oral CP for steroid resistant nephrotic syndrome [abstract no: OFC44]. Pediatric Nephrology 2004;19(9):C73. [CENTRAL: CN-00653731]x-wiley/crsRef/3333579
57. Mantan M, Sriram CS, Hari P, Dinda A, Bagga A. Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome. Pediatric Nephrology 2008;23(9):1495-502. [MEDLINE: 18566839]x-wiley/crsRef/3333580
58. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney International 1993;43(6):1377-84. [MEDLINE: 8315953]x-wiley/crsRef/3333582
59. Ohri A, Phatarpekar A, Ali U, Tembekar Y. Randomized controlled trial of oral versus intravenous cyclophosphamide in idiopathic steroid resistant nephrotic syndrome [abstract no: 424]. Pediatric Nephrology 2010;25(9):1879. [EMBASE: 70438526]x-wiley/crsRef/12315212
60. Shah KM, Ohri AJ, Ali US. A randomized controlled trial of intravenous versus oral cyclophosphamide in steroid-resistant nephrotic syndrome in children. Indian Journal of Nephrology 2017;27(6):430-4. [MEDLINE: 29217878]x-wiley/crsRef/12315213
61. Bagga A, Gupta A, Dinda A, Hari P, Sinha A. Randomized controlled trial comparing efficacy of mycophenolate mofetil (MMF) & alternate day prednisone versus tacrolimus & prednisolone in maintaining remission in steroid resistant nephrotic syndrome (SRNS) [abstract no: P-SUN200]. Pediatric Nephrology 2013;28(8):1600. x-wiley/crsRef/12315215
62. Sinha A, Bagga A. Randomized trial on efficacy of mycophenolate mofetil versus tacrolimus in maintaining remission in children in steroid resistant nephrotic syndrome [abstract no: HI-OR05]. Journal of the American Society of Nephrology 2015;26(Abstract Suppl):B2. x-wiley/crsRef/12315216
63. Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome. Kidney International 2017;92(1):248-57. [MEDLINE: 28318625]x-wiley/crsRef/12315217
64. Medeiros M, Fuentes Y, Valverde S, Hernandez AM. Superior results with tacrolimus than ciclosporine in children with steroid resistant nephrotic syndrome [abstract no: SA-PO2854]. Journal of the American Society of Nephrology 2011;22(Abstract Suppl):774A. x-wiley/crsRef/12315219
65. Valverde S, Hernandez AM, Velasquez L, Romero B, Mendoza A, Ramon G, et al. Efficacy of prednisone-tacrolimus vs. prednisone-cyclosporine in steroid-resistant nephrotic syndrome [abstract no: 47]. Pediatric Nephrology 2010;25(9):1804. [EMBASE: 70438149]x-wiley/crsRef/12315220
66. Wu B, Mao J, Shen H, Fu H, Wang J, Liu A, et al. Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing. Nephrology 2015;20(1):18-24. [MEDLINE: 25312783]x-wiley/crsRef/3333584
67. Li ZH, Yi ZW. Clinical study of fosinopril in children with steroid resistant nephrotic syndrome [abstract no: 2344]. 23rd International Congress of Paediatrics; 2001 Sep 9-14; Beijing, China. 2001. [CENTRAL: CN-00445802]x-wiley/crsRef/3333587
68. Li ZH, Yi ZW. Clinical study of fosinopril in children with steroid resistant nephrotic syndrome [abstract no: P225]. Pediatric Nephrology 2001;16(8):C114. x-wiley/crsRef/3333586
69. Yi Z, Li Z, Wu XC, He QN, Dang XQ, He XJ. Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome. Pediatric Nephrology 2006;21(7):967-72. [MEDLINE: 16773409]x-wiley/crsRef/3333588
70. Adeniyi A, Hendrickse RG, Soothill JF. A controlled trial of cyclophosphamide and azathioprine in Nigerian children with the nephrotic syndrome and poorly selective proteinuria. Archives of Disease in Childhood 1979;54(3):204-7. [MEDLINE: 373645]x-wiley/crsRef/3333590
71. Ahn YH, Kang HG, Kim SH. Efficacy and safety of rituximab in children with refractory nephrotic syndrome: a multicenter clinical trial [abstract]. Kidney Research & Clinical Practice 2014;33(2):A1. x-wiley/crsRef/12315222
72. Ahn YH, Kim SH, Han KH, Cho HY, Shin JI, Cho MH, et al. Efficacy and safety of rituximab in children with refractory nephrotic syndrome: a multicenter clinical trial [abstract no: 039]. Pediatric Nephrology 2013;28(8):1361. [EMBASE: 71126980]x-wiley/crsRef/12315223
73. Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine 2018;97(46):e13157. [PUBMED: 30431588]x-wiley/crsRef/12315224
74. Arora A, Ahlawat RS, Arora S, Arora N, Mandel AK. Randomised controlled study of enalapril in steroid resistant nephrotic syndrome. Indian Journal of Nephrology 2002;12(3):107-12. [CENTRAL: CN-00460300]x-wiley/crsRef/3333592
75. Buyukcelik M, Anarat A, Bayazit AK, Noyan A, Ozel A, Anarat R, et al. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics 2002;44(1):40-4. [MEDLINE: 11858378]x-wiley/crsRef/3333596
76. Hari P, Khandelwal P, Satpathy A, Hari S, Thergaonkar R, Lakshmy R, et al. Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial. Pediatric Nephrology 2018;33(12):2299-309. [MEDLINE: 30091061]x-wiley/crsRef/12315226
77. Hari P, Satpathy A, Thergaonkar R, Khandelwal P, Hari S, Lakshmy R, et al. Effect of atorvastatin on lipid profile and carotid intima media thickness (cIMT) in children with refractory nephrotic syndrome: a randomized double blind, placebo controlled trial [abstract no: FP-S14-3]. Pediatric Nephrology 2016;31(10):1737-8. [EMBASE: 612479933]x-wiley/crsRef/12315227
78. Hiraoka M, Sudo M, West Japanese Cooperative Study of Kidney Disease in Children. Low versus standard dosage of prednisolone for initial treatment of idiopathic nephrotic syndrome in children [abstract no: A0445]. Journal of the American Society of Nephrology 1996;7(9):1335. x-wiley/crsRef/3333602
79. Hiraoka M, Tsukahara H, Haruki S, Hayashi S, Takeda N, Miyagawa K, et al. Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome. The West Japan Cooperative Study of Kidney Disease in Children. Kidney International 2000;58(3):1247-52. [MEDLINE: 10972687]x-wiley/crsRef/3333603
80. Hiraoka M, Tsukahara H, Haruki S, Hayashi S, Takeda N, Miyagawa K, et al. Older boys benefit from intensive initial prednisolone therapy for nephrotic syndrome [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):103A. [CENTRAL: CN-00550605]x-wiley/crsRef/3333604
81. Iyengar A, Damle H, Kulkarni C, Damle L, Phadke K. Steroid sparing effect of a herbal preparation in steroid-dependent nephrotic syndrome. Pediatric Nephrology 2006;21(7):1031-3. [MEDLINE: 16773418]x-wiley/crsRef/3333606
82. Ito S. A combination of cyclosporine and prednisolone and a combination of methylprednisolone, cyclosporine and prednisolone for steroid-resistant nephrotic syndrome in children: A randomized controlled study. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000010 (first received 1 August 2005). x-wiley/crsRef/12315229
83. Jung A. Immunomodulatory treatment in children with steroid-dependent/steroid-resistant nephrotic syndrome [abstract no: 170]. European Journal of Clinical Investigation 1990;20(2 Pt II):A 33. [CENTRAL: CN-00253605]x-wiley/crsRef/3333608
84. Kano K, Nishikura K, Yamada Y, Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clinical Nephrology 2003;60(2):85-9. [MEDLINE: 12940609]x-wiley/crsRef/3333611
85. Kano K, Nishikura K, Yamada Y, Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria [abstract no: T756-757]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):524-5. x-wiley/crsRef/3333610
86. Kano K, Nishikura K, Yamada Y, Arisaka O. Effect of fluvastatin on proteinuria [abstract no: M-PO20068]. Nephrology 2005;10(Suppl 1):A33. [CENTRAL: CN-00774540]x-wiley/crsRef/3333612
87. Kano K, Nishikura K, Yamada Y, Arisaka O. No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. Clinical Nephrology 2005;63(2):74-9. [MEDLINE: 15730048]x-wiley/crsRef/3333613
88. Khemani S, Moorani KN. Cyclosporine versus cyclophosphamide in childhood nephrotic syndrome. Journal of the Liaquat University of Medical & Health Sciences 2016;15(2):57-62. [EMBASE: 611436094]x-wiley/crsRef/12315231
89. Koshikawa S. Clinical evaluation of an immunosuppressive drug, mizoribine (HE-69) on steroid resistant nephrotic syndrome - a multicenter double-blind comparison study with placebo. Jin to Toseki [Kidney and Dialysis] 1993;34:631-50. [CENTRAL: CN-00602134]x-wiley/crsRef/3333615
90. Kumar NS, Mishra RN, Singh AK, Prakash J. Effect of ACE inhibitor and calcium channel blocker on proteinuria in subjects with steroid resistant idiopathic nephrotic syndrome [abstract no: CNO-20]. Indian Journal of Nephrology 2001;11(3):110-1. [CENTRAL: CN-00461120]x-wiley/crsRef/3333617
91. Kumar NS, Singh AK, Mishra RN, Prakash J. Comparative study of angiotensin converting enzyme inhibitor and calcium channel blocker in the treatment of steroid-resistant idiopathic nephrotic syndrome. Journal of the Association of Physicians of India 2004;52:454-8. [MEDLINE: 15645954]x-wiley/crsRef/3333618
92. Li X, He Q, Lin W, Wang S, Chen J. Therapy of tacrolimus in steroid-resistant minimal-change nephrotic syndrome: a randomized controlled clinical trial [abstract no: F-PO1105]. Journal of the American Society of Nephrology 2006;17(Abstracts):569A. [CENTRAL: CN-01657685]x-wiley/crsRef/3333620
93. Ren HQ, Zhong YF, Li Y, Cai Q, Han SJ, Hao XK, et al. Low-dose tacrolimus combined with tripterygium in treatment of steroid-resistant nephrotic syndrome: a prospective randomized controlled trial. Academic Journal of Second Military Medical University 2011;32(12):1340-5. [EMBASE: 2011698533]x-wiley/crsRef/3333624
94. Ren H, Shen P, Li X, Pan X, Zhang W, Chen N. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. American Journal of Nephrology 2013;37(1):84-90. [MEDLINE: 23343906]x-wiley/crsRef/3333626
95. Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, et al. Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial. Clinical & Experimental Nephrology 2014;18(5):784-94. [MEDLINE: 24363128]x-wiley/crsRef/3333628
96. Saito T, Mitarai T, Yokoyama H, Yorioka N, Iwano M, Nishi S, et al. Effect of preprandial once-a-day administration of cyclosporine (CyA) for steroid resistant nephrotic syndrome (SRNS) [abstract no: SA-PO997]. Journal of the American Society of Nephrology 2007;18(Abstracts):562A. [CENTRAL: CN-01657682]x-wiley/crsRef/12315232
97. Saito T, Watanabe M, Ogahara S, Shuto H, Kataoka H. Benefits of once-a-day preprandial administration and C2 monitoring for the cyclosporine (CyA) treatment of idiopathic membranous nephropathy (IMN) with steroid resistant nephrotic syndrome (SRNS) [abstract no: SA-PO2293]. Journal of the American Society of Nephrology 2009;20(Abstract Suppl):634A. x-wiley/crsRef/12315233
98. Saito T, Watanabe M, Ogahara S, Shuto H, Kataoka Y. Significance of blood concentration of cyclosporine at 2 hours after administration for the treatment of idiopathic membranous nephropathy with steroid resistant nephrotic syndrome [abstract no: SA285]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01657683]x-wiley/crsRef/3333630
99. Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, et al. Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. Clinical & Experimental Nephrology 2017;21(6):961-70. [MEDLINE: 27783276]x-wiley/crsRef/12315235
100. Saito T, Watanabe M, Ogahara S, Shuto H, Kataoka Y. Effects of mizoribin combined with prednisolone for the treatment of idiopathic membranous nephropathy with steroid resistant nephrotic syndrome [abstract no: Su363]. NDT Plus 2010;3(Suppl 3):iii430-1. [EMBASE: 70484583]x-wiley/crsRef/12315236
101. Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, et al. A randomized open-label comparative study of conventional therapy versus mizoribine only therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clinical & Experimental Nephrology 2004;8(2):117-26. [MEDLINE: 15235928]x-wiley/crsRef/3333632
102. Tejani A, Gonzalez R, Rajpoot D, Sharma R, Pomrantz A. A randomized trial of cyclosporine with low-dose prednisone compared with high-dose prednisone in nephrotic syndrome. Transplantation Proceedings 1988;20(3 Suppl 4):262-4. [MEDLINE: 3381280]x-wiley/crsRef/12315238
103. Tejani A, Suthanthiran M, Pomrantz A. A randomized controlled trial of low-dose prednisone and ciclosporin versus high-dose prednisone in nephrotic syndrome of children. Nephron 1991;59(1):96-9. [MEDLINE: 1944755]x-wiley/crsRef/12315239
104. Tejani A, Suthanthiran M, Rajpoot D, Gonzalez R, Pomrantz A. Randomized trial of cylosporine and low dose prednisone (P&CS) vs conventional prednisone (P) therapy in recent onset (< 1 yr) nephrotic syndrome (NS) [abstract]. Kidney International 1989;35(1):213. [CENTRAL: CN-01912553]x-wiley/crsRef/12315240
105. Walker RG, Kincaid-Smith P. Cyclosporin a (Cy-A) treatment in focal and segmental hyalinosis and sclerosis (FSHS): a controlled trial [abstract no: 17]. Kidney International 1989;36(6):1162. [CENTRAL: CN-00509552]x-wiley/crsRef/12315242
106. Walker RG, Kincaid-Smith P. The effect of treatment of corticosteroid-resistant idiopathic (primary) focal and segmental hyalinosis and sclerosis (focal glomerulosclerosis) with ciclosporin. Nephron 1990;54(2):117-21. [MEDLINE: 2179754]x-wiley/crsRef/12315243
107. Yi ZW, Wu XC, Xu H, Zhou LJ, Wu YB, Feng SP, et al. A prospective multicenter clinical control trial on treatment of refractory nephrotic syndrome with mycophenolate mofetil in children. Zhongguo Dangdai Erke Zazhi 2008;10(5):575-8. [MEDLINE: 18947472]x-wiley/crsRef/12315245
108. Zhao K, Li Q, Ma Q, Zhang L, Duan Y. Treatment with tacrolimus and prednisone is preferable to intravenous cyclophosphamide for children with difficult-to-treat nephrotic syndrome [abstract no: P-SUN205]. Pediatric Nephrology 2013;28(8):1601-2. [EMBASE: 71127684]x-wiley/crsRef/3333637
109. Komers R. Study of sparsentan in patients with primary focal segmental glomerulosclerosis (FSGS) (DUPLEX). www.clinicaltrials.gov/ct2/show/NCT03493685 (first received 10 April 2018). x-wiley/crsRef/12315247
110. Basu B. Efficacy and safety of rituximab to that of calcineurin inhibitors in children with steroid resistant nephrotic syndrome. www.clinicaltrials.gov/ct2/show/NCT02382575 2015; Vol. (first received 5 March 2015). x-wiley/crsRef/3333644
111. Ghiggeri GM. Ofatumumab in children with drug resistant idiopathic nephrotic syndrome. www.clinicaltrials.gov/ct2/show/NCT02394106 2015; Vol. (first received 20 March 2015). x-wiley/crsRef/3333646
112. Li Y. Availability study of ACTH to treat children SRNS/SDNS. www.clinicalTrials.gov/show/NCT02972346 (first received 23 November 2016). x-wiley/crsRef/12315249
113. Trachtman H, Gipson DS, Somers M, Spino C, Adler S, Holzman L, et al. Randomized clinical trial design to assess abatacept in resistant nephrotic syndrome. Kidney International Reports 2018;3(1):115-21. [MEDLINE: 29340321]x-wiley/crsRef/12315251
114. Bierzynska A, McCarthy HJ, Soderquest K, Sen ES, Colby C, Ding WY, et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney International 2017;91(4):937-47. [MEDLINE: 28117080]
115. Büscher AK, Kranz B, Büscher R, Hildebrandt F, Dworniczak B, Pennekamp P, et al. Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clinical Journal of the American Society of Nephrology: CJASN 2010;5(11):2075-84. [MEDLINE: 20798252]
116. Chanchlani R, Parekh RS. Ethnic differences in childhood nephrotic syndrome. Frontiers in Pediatrics 2016;4:39. [MEDLINE: 27148508]
117. Chua A, Yorgin P. Steroid-resistant nephrotic syndrome. In: Molony DA, Craig JC editor(s). Evidence-Based Nephrology. Oxford: Wiley-Blackwell, 2009:787-805.
118. Colquitt JL, Kirby J, Green C, Cooper K, Trompeter RS. The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Health Technology Assessment (Winchester, England) 2007;11(21):1-93. [MEDLINE: 17537341]
119. Deegens JK, Wetzels JF. Immunosuppressive treatment of focal and segmental glomerulosclerosis: lessons from a randomized controlled trial. Kidney International 2011;80(8):798-801. [MEDLINE: 21960168]
120. Ding WY, Koziell A, McCarthy HJ, Bierzynska A, Bhagavatula MK, Dudley JA, et al. Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. Journal of the American Society of Nephrology 2014;25(6):1342–8. [MEDLINE: 24511128]
121. Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellerman J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrology Dialysis Transplantation 2007;22(8):2183-93. [MEDLINE: 17504846]
122. El Bakkali L, Rodrigues Pereira R, Kuik DJ, Ket JC, van Wijk JA. Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature. Pediatric Nephrology 2011;26(8):1241-6. [MEDLINE: 21533870]
123. Gellermann J, Ehrich JH, Querfeld U. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrology Dialysis Transplantation 2012;27(5):1970-8. [MEDLINE: 21976740]
124. Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, et al. Differential risk of remission and ESRD in childhood FSGS. Pediatric Nephrology 2006;21(3):344-9. [MEDLINE: 16395603]
125. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: 18436948]
126. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [MEDLINE: 21195583]
127. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
128. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
129. Hollis S, Cambell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4. [MEDLINE: 10480822]
130. Inaba A, Hamasaki Y, Ishikura K, Hamada R, Sakai T, Hataya H, et al. Long-term outcome of idiopathic steroid-resistant nephrotic syndrome in children. Pediatric Nephrology 2016;31(3):425-34. [MEDLINE: 26335197]
131. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. Journal of Pediatrics 1981;98(4):561-4. [MEDLINE: 7205481]
132. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney International Supplements 2012;2:139-274.
133. Kemper MJ, Valentin L, van Husen M. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options. Pediatric Nephrology 2018;33(10):1641-9. [MEDLINE: 28879428]
134. Koskimies O, Vilska J, Rapola J, Hallman N. Long-term outcome of primary nephrotic syndrome. Archives of Disease in Childhood 1982;57(7):544-8. [MEDLINE: 7103547]
135. Lombel RM, Hodson EM, Gipson DS, Kidney Disease: Improving Global Outcomes. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatric Nephrology 2013;28(3):409-14. [MEDLINE: 23052648]
136. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13. [MEDLINE: 9746022]
137. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. Journal of Pediatrics 1994;125(6 Pt 1):981-6. [MEDLINE: 7996374]
138. Pelletier JH, Kumar KR, Engen R, Bensimhon A, Varner JD, Rheault MN, et al. Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings [Erratum in: Pediatr Nephrol. 2019 Mar;34(3):539; PMID: 30443740]. Pediatric Nephrology 2018;33(10):1773-80. [MEDLINE: 29982878]
139. Sadowski CE, Lovric S, Ashraf S, Pabst WL, Gee HY, Kohl S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. Journal of the American Society of Nephrology 2015;26(6):1279-89. [MEDLINE: 25349199]
140. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [MEDLINE: 7823387]
141. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
142. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
143. Sureshkumar P, Hodson EM, Willis NS, Barzi F, Craig JC. Predictors of remission and relapse in idiopathic nephrotic syndrome: a prospective cohort study. Pediatric Nephrology 2014;29(6):1039-46. [MEDLINE: 24488504]
144. Thalgahagoda S, Abeyagunawardena S, Jayaweera H, Karunadasa UI, Abeyagunawardena AS. Pulsed vincristine therapy in steroid-resistant nephrotic syndrome. BioMed Research International 2017;2017:1757940. [MEDLINE: 28630858]
145. Trautmann A, Bodria M, Ozaltin F, Gheisari A, Melk A, Azocar M, et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clinical Journal of The American Society of Nephrology: CJASN 2015;10(4):592-600. [MEDLINE: 25635037]
146. Trautmann, A, Schnaidt S, Lipska-Ziętkiewicz BS, Bodria M, Ozaltin F, et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. Journal of the American Society of Nephrology 2017;28(10):3055–65. [MEDLINE: 28566477]
147. Troost JP, Trachtman H, Nachman PH, Kretzler M, Spino C, Komers R, et al. An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN 2018;13(3):414-21. [MEDLINE: 29167190]
148. Tune BM, Lieberman E, Mendoza SA. Steroid-resistant nephrotic focal segmental glomerulosclerosis: a treatable disease. Pediatric Nephrology 1996;10(6):772-8. [MEDLINE: 8971906]
149. Wong W. Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study. Journal of Paediatrics & Child Health 2007;43(5):337-41. [MEDLINE: 17489822]
150. Habashy D, Hodson E, Craig J. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD003594]
151. Habashy D, Hodson EM, Craig JC. Interventions for steroid-resistant nephrotic syndrome: a systematic review. Pediatric Nephrology 2003;18(9):906-12. [MEDLINE: 12836096]
152. Habashy D, Hodson E, Craig J. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD003594.pub2]
153. Habashy D, Hodson E, Craig J. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD003594.pub3]
154. Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD003594.pub4]
155. Hodson EM, Wong SC, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2016, Issue 10. [DOI: 10.1002/14651858.CD003594.pub5]